Qiagen N.V. Logo

Qiagen N.V.

QIA.DE

(1.5)
Stock Price

39,18 EUR

2.61% ROA

2% ROE

132.61x PER

Market Cap.

9.675.090.778,57 EUR

41.16% DER

5.96% Yield

3.75% NPM

Qiagen N.V. Stock Analysis

Qiagen N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Qiagen N.V. Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 DER

The stock has a minimal amount of debt (40%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

ROE in an average range (9.27%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 PBV

The stock's PBV ratio (2.43x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-332) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Qiagen N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Qiagen N.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Qiagen N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Qiagen N.V. Revenue
Year Revenue Growth
1995 37.000.000
1996 54.200.000 31.73%
1997 74.300.000 27.05%
1998 110.200.000 32.58%
1999 143.960.000 23.45%
2000 204.031.000 29.44%
2001 263.770.000 22.65%
2002 298.607.000 11.67%
2003 351.404.000 15.02%
2004 380.629.000 7.68%
2005 398.395.000 4.46%
2006 465.778.000 14.47%
2007 649.774.000 28.32%
2008 892.975.000 27.23%
2009 1.009.825.000 11.57%
2010 1.087.431.000 7.14%
2011 1.169.747.000 7.04%
2012 1.254.456.000 6.75%
2013 1.301.984.000 3.65%
2014 1.344.777.000 3.18%
2015 1.280.986.000 -4.98%
2016 1.337.991.000 4.26%
2017 1.417.536.000 5.61%
2018 1.501.848.000 5.61%
2019 1.526.424.000 1.61%
2020 1.870.346.000 18.39%
2021 2.251.657.000 16.93%
2022 2.141.518.000 -5.14%
2023 1.903.576.000 -12.5%
2023 1.965.311.000 3.14%
2024 1.985.388.000 1.01%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Qiagen N.V. Research and Development Expenses
Year Research and Development Expenses Growth
1995 4.400.000
1996 6.500.000 32.31%
1997 8.300.000 21.69%
1998 12.800.000 35.16%
1999 16.271.000 21.33%
2000 22.212.000 26.75%
2001 26.769.000 17.02%
2002 28.177.000 5%
2003 31.789.000 11.36%
2004 34.159.000 6.94%
2005 39.100.000 12.64%
2006 41.560.000 5.92%
2007 64.935.000 36%
2008 97.331.000 33.28%
2009 107.900.000 9.8%
2010 126.040.000 14.39%
2011 130.636.000 3.52%
2012 122.476.000 -6.66%
2013 146.070.000 16.15%
2014 163.627.000 10.73%
2015 147.180.000 -11.17%
2016 176.135.000 16.44%
2017 154.084.000 -14.31%
2018 161.852.000 4.8%
2019 157.448.000 -2.8%
2020 139.060.000 -13.22%
2021 189.964.000 26.8%
2022 189.859.000 -0.06%
2023 191.736.000 0.98%
2023 198.511.000 3.41%
2024 196.412.000 -1.07%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Qiagen N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 18.400.000
1996 27.000.000 31.85%
1997 37.700.000 28.38%
1998 50.000.000 24.6%
1999 61.261.000 18.38%
2000 82.173.000 25.45%
2001 100.852.000 18.52%
2002 117.116.000 13.89%
2003 125.274.000 6.51%
2004 129.221.000 3.05%
2005 134.812.000 4.15%
2006 164.516.000 18.06%
2007 236.622.000 30.47%
2008 341.344.000 30.68%
2009 115.933.000 -194.43%
2010 110.009.000 -5.39%
2011 185.507.000 40.7%
2012 152.068.000 -21.99%
2013 199.072.000 23.61%
2014 126.550.000 -57.31%
2015 103.874.000 -21.83%
2016 129.248.000 19.63%
2017 200.098.000 35.41%
2018 141.214.000 -41.7%
2019 112.262.000 -25.79%
2020 110.153.000 -1.91%
2021 128.076.000 13.99%
2022 129.725.000 1.27%
2023 114.596.000 -13.2%
2023 119.254.000 3.91%
2024 114.472.000 -4.18%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Qiagen N.V. EBITDA
Year EBITDA Growth
1995 6.000.000
1996 6.300.000 4.76%
1997 8.900.000 29.21%
1998 17.900.000 50.28%
1999 38.025.000 52.93%
2000 65.726.000 42.15%
2001 68.119.000 3.51%
2002 96.790.000 29.62%
2003 97.197.000 0.42%
2004 124.483.000 21.92%
2005 130.732.000 4.78%
2006 150.290.000 13.01%
2007 238.891.000 37.09%
2008 280.432.000 14.81%
2009 304.121.000 7.79%
2010 216.486.000 -40.48%
2011 132.462.000 -63.43%
2012 204.722.000 35.3%
2013 103.715.000 -97.39%
2014 194.914.000 46.79%
2015 361.367.000 46.06%
2016 308.986.000 -16.95%
2017 380.508.000 18.8%
2018 499.466.000 23.82%
2019 567.676.000 12.02%
2020 764.872.000 25.78%
2021 923.003.000 17.13%
2022 824.123.000 -12%
2023 693.752.000 -18.79%
2023 723.864.000 4.16%
2024 -364.224.000 298.74%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Qiagen N.V. Gross Profit
Year Gross Profit Growth
1995 29.300.000
1996 42.000.000 30.24%
1997 59.200.000 29.05%
1998 83.200.000 28.85%
1999 111.830.000 25.6%
2000 155.065.000 27.88%
2001 184.097.000 15.77%
2002 202.099.000 8.91%
2003 229.000.000 11.75%
2004 253.517.000 9.67%
2005 275.201.000 7.88%
2006 324.610.000 15.22%
2007 433.547.000 25.13%
2008 599.690.000 27.7%
2009 667.073.000 10.1%
2010 715.562.000 6.78%
2011 749.809.000 4.57%
2012 824.024.000 9.01%
2013 815.490.000 -1.05%
2014 864.938.000 5.72%
2015 826.375.000 -4.67%
2016 844.653.000 2.16%
2017 922.561.000 8.44%
2018 1.000.960.000 7.83%
2019 1.005.262.000 0.43%
2020 1.227.810.000 18.13%
2021 1.450.820.000 15.37%
2022 1.384.563.000 -4.79%
2023 1.191.840.000 -16.17%
2023 1.233.688.000 3.39%
2024 139.056.000 -787.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Qiagen N.V. Net Profit
Year Net Profit Growth
1995 2.400.000
1996 5.300.000 54.72%
1997 8.800.000 39.77%
1998 12.400.000 29.03%
1999 12.617.000 1.72%
2000 20.106.000 37.25%
2001 34.419.000 41.58%
2002 23.142.000 -48.73%
2003 42.850.000 45.99%
2004 48.705.000 12.02%
2005 62.225.000 21.73%
2006 70.539.000 11.79%
2007 50.122.000 -40.73%
2008 89.033.000 43.7%
2009 137.767.000 35.37%
2010 144.311.000 4.53%
2011 96.038.000 -50.26%
2012 129.506.000 25.84%
2013 69.073.000 -87.49%
2014 116.634.000 40.78%
2015 127.103.000 8.24%
2016 80.404.000 -58.08%
2017 40.394.000 -99.05%
2018 190.380.000 78.78%
2019 -41.455.000 559.24%
2020 73.640.000 156.29%
2021 512.599.000 85.63%
2022 423.211.000 -21.12%
2023 311.272.000 -35.96%
2023 341.303.000 8.8%
2024 -733.840.000 146.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Qiagen N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 1 0%
2010 1 0%
2011 0 0%
2012 1 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 0 0%
2020 0 0%
2021 2 100%
2022 2 -100%
2023 1 0%
2023 2 0%
2024 -3 133.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Qiagen N.V. Free Cashflow
Year Free Cashflow Growth
1995 2.200.000
1996 -5.600.000 139.29%
1997 1.700.000 429.41%
1998 1.100.000 -54.55%
1999 14.365.000 92.34%
2000 -573.000 2606.98%
2001 -43.980.000 98.7%
2002 -22.450.000 -95.9%
2003 44.502.000 150.45%
2004 41.177.000 -8.07%
2005 77.509.000 46.87%
2006 66.126.000 -17.21%
2007 26.197.000 -152.42%
2008 115.081.000 77.24%
2009 147.638.000 22.05%
2010 126.843.000 -16.39%
2011 123.391.000 -2.8%
2012 116.795.000 -5.65%
2013 140.264.000 16.73%
2014 190.962.000 26.55%
2015 200.016.000 4.53%
2016 247.678.000 19.24%
2017 162.374.000 -52.54%
2018 208.733.000 22.21%
2019 55.959.000 -273.01%
2020 188.035.000 70.24%
2021 432.467.000 56.52%
2022 565.928.000 23.58%
2023 296.653.000 -90.77%
2023 83.641.000 -254.67%
2024 127.707.000 34.51%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Qiagen N.V. Operating Cashflow
Year Operating Cashflow Growth
1995 3.900.000
1996 4.100.000 4.88%
1997 8.500.000 51.76%
1998 11.600.000 26.72%
1999 26.176.000 55.68%
2000 38.872.000 32.66%
2001 58.087.000 33.08%
2002 36.686.000 -58.34%
2003 64.060.000 42.73%
2004 53.798.000 -19.08%
2005 91.237.000 41.03%
2006 101.479.000 10.09%
2007 84.811.000 -19.65%
2008 172.998.000 50.98%
2009 216.995.000 20.28%
2010 250.752.000 13.46%
2011 244.779.000 -2.44%
2012 244.880.000 0.04%
2013 258.957.000 5.44%
2014 287.965.000 10.07%
2015 317.497.000 9.3%
2016 341.602.000 7.06%
2017 286.779.000 -19.12%
2018 359.496.000 20.23%
2019 330.843.000 -8.66%
2020 492.272.000 32.79%
2021 639.001.000 22.96%
2022 715.264.000 10.66%
2023 459.455.000 -55.68%
2023 124.684.000 -268.5%
2024 166.617.000 25.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Qiagen N.V. Capital Expenditure
Year Capital Expenditure Growth
1995 1.700.000
1996 9.700.000 82.47%
1997 6.800.000 -42.65%
1998 10.500.000 35.24%
1999 11.811.000 11.1%
2000 39.445.000 70.06%
2001 102.067.000 61.35%
2002 59.136.000 -72.6%
2003 19.558.000 -202.36%
2004 12.621.000 -54.96%
2005 13.728.000 8.06%
2006 35.353.000 61.17%
2007 58.614.000 39.69%
2008 57.917.000 -1.2%
2009 69.357.000 16.49%
2010 123.909.000 44.03%
2011 121.388.000 -2.08%
2012 128.085.000 5.23%
2013 118.693.000 -7.91%
2014 97.003.000 -22.36%
2015 117.481.000 17.43%
2016 93.924.000 -25.08%
2017 124.405.000 24.5%
2018 150.763.000 17.48%
2019 274.884.000 45.15%
2020 304.237.000 9.65%
2021 206.534.000 -47.31%
2022 149.336.000 -38.3%
2023 162.802.000 8.27%
2023 41.043.000 -296.66%
2024 38.910.000 -5.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Qiagen N.V. Equity
Year Equity Growth
1995 12.200.000
1996 47.700.000 74.42%
1997 54.000.000 11.67%
1998 73.100.000 26.13%
1999 92.662.000 21.11%
2000 164.578.000 43.7%
2001 212.975.000 22.72%
2002 263.031.000 19.03%
2003 334.786.000 21.43%
2004 400.376.000 16.38%
2005 450.457.000 11.12%
2006 566.165.000 20.44%
2007 1.392.128.000 59.33%
2008 1.453.844.000 4.25%
2009 2.291.169.000 36.55%
2010 2.476.353.000 7.48%
2011 2.557.798.000 3.18%
2012 2.724.363.000 6.11%
2013 2.723.871.000 -0.02%
2014 2.657.999.000 -2.48%
2015 2.561.954.000 -3.75%
2016 2.607.096.000 1.73%
2017 2.540.996.000 -2.6%
2018 2.634.970.000 3.57%
2019 2.536.591.000 -3.88%
2020 2.483.049.000 -2.16%
2021 3.096.550.000 19.81%
2022 3.466.611.000 10.68%
2023 3.807.764.000 8.96%
2023 3.693.700.000 -3.09%
2024 3.405.263.000 -8.47%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Qiagen N.V. Assets
Year Assets Growth
1995 26.200.000
1996 66.200.000 60.42%
1997 78.900.000 16.1%
1998 106.700.000 26.05%
1999 148.117.000 27.96%
2000 230.261.000 35.67%
2001 356.968.000 35.5%
2002 454.511.000 21.46%
2003 551.930.000 17.65%
2004 714.599.000 22.76%
2005 765.298.000 6.62%
2006 1.212.012.000 36.86%
2007 2.775.174.000 56.33%
2008 2.885.323.000 3.82%
2009 3.796.464.000 24%
2010 3.913.995.000 3%
2011 3.756.453.000 -4.19%
2012 4.125.948.000 8.96%
2013 4.088.392.000 -0.92%
2014 4.454.372.000 8.22%
2015 4.189.678.000 -6.32%
2016 4.308.194.000 2.75%
2017 5.038.516.000 14.49%
2018 5.748.332.000 12.35%
2019 5.235.616.000 -9.79%
2020 5.971.198.000 12.32%
2021 6.146.954.000 2.86%
2022 6.287.735.000 2.24%
2023 6.115.190.000 -2.82%
2023 5.906.698.000 -3.53%
2024 5.584.640.000 -5.77%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Qiagen N.V. Liabilities
Year Liabilities Growth
1995 14.000.000
1996 18.500.000 24.32%
1997 24.900.000 25.7%
1998 33.600.000 25.89%
1999 55.455.000 39.41%
2000 65.683.000 15.57%
2001 143.993.000 54.38%
2002 191.480.000 24.8%
2003 217.144.000 11.82%
2004 314.223.000 30.89%
2005 314.841.000 0.2%
2006 645.847.000 51.25%
2007 1.383.046.000 53.3%
2008 1.431.479.000 3.38%
2009 1.505.295.000 4.9%
2010 1.437.642.000 -4.71%
2011 1.198.655.000 -19.94%
2012 1.401.585.000 14.48%
2013 1.364.521.000 -2.72%
2014 1.796.373.000 24.04%
2015 1.627.724.000 -10.36%
2016 1.701.098.000 4.31%
2017 2.497.520.000 31.89%
2018 3.113.362.000 19.78%
2019 2.699.025.000 -15.35%
2020 3.488.149.000 22.62%
2021 3.050.404.000 -14.35%
2022 2.821.124.000 -8.13%
2023 2.307.426.000 -22.26%
2023 2.212.998.000 -4.27%
2024 2.179.377.000 -1.54%

Qiagen N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.78
Net Income per Share
0.33
Price to Earning Ratio
132.61x
Price To Sales Ratio
4.99x
POCF Ratio
16.74
PFCF Ratio
23.88
Price to Book Ratio
2.83
EV to Sales
5.43
EV Over EBITDA
23.62
EV to Operating CashFlow
18.31
EV to FreeCashFlow
26.02
Earnings Yield
0.01
FreeCashFlow Yield
0.04
Market Cap
9,68 Bil.
Enterprise Value
10,54 Bil.
Graham Number
10.68
Graham NetNet
-3.9

Income Statement Metrics

Net Income per Share
0.33
Income Quality
7.92
ROE
0.02
Return On Assets
0.01
Return On Capital Employed
0.02
Net Income per EBT
0.75
EBT Per Ebit
1.31
Ebit per Revenue
0.04
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0.06
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.48
Operating Profit Margin
0.04
Pretax Profit Margin
0.05
Net Profit Margin
0.04

Dividends

Dividend Yield
0.06
Dividend Yield %
5.96
Payout Ratio
0
Dividend Per Share
2.6

Operating Metrics

Operating Cashflow per Share
2.6
Free CashFlow per Share
1.83
Capex to Operating CashFlow
0.3
Capex to Revenue
0.09
Capex to Depreciation
0.81
Return on Invested Capital
0.01
Return on Tangible Assets
0.03
Days Sales Outstanding
66.84
Days Payables Outstanding
27.75
Days of Inventory on Hand
117.39
Receivables Turnover
5.46
Payables Turnover
13.15
Inventory Turnover
3.11
Capex per Share
0.77

Balance Sheet

Cash per Share
4,03
Book Value per Share
15,41
Tangible Book Value per Share
2.76
Shareholders Equity per Share
15.41
Interest Debt per Share
6.55
Debt to Equity
0.41
Debt to Assets
0.25
Net Debt to EBITDA
1.94
Current Ratio
1.77
Tangible Asset Value
0,61 Bil.
Net Current Asset Value
-0,35 Bil.
Invested Capital
4307501000
Working Capital
0,79 Bil.
Intangibles to Total Assets
0.5
Average Receivables
0,35 Bil.
Average Payables
0,08 Bil.
Average Inventory
361747500
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Qiagen N.V. Dividends
Year Dividends Growth
2017 1
2024 3 50%

Qiagen N.V. Profile

About Qiagen N.V.

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

CEO
Mr. Thierry Bernard
Employee
5.900
Address
Hulsterweg 82
Venlo, 5912 PL

Qiagen N.V. Executives & BODs

Qiagen N.V. Executives & BODs
# Name Age
1 Ms. Stephany Foster
Senior Vice President & Head of Human Resources
70
2 Mr. Fernando Beils
Senior Vice President & Head of the Molecular Diagnostics Business Area
70
3 Mr. John Gilardi
Vice President of Corporate Communications & Investor Relations
70
4 Dr. Jonathan G. Sheldon Ph.D.
Senior Vice President & Head of the QIAGEN Digital Insights Business Area
70
5 Dr. Thomas Theuringer
Senior Director & Head of External Communications
70
6 Mr. Jean-Pascal Viola
Senior Vice President & Head of Corporate Strategy and Business Development
70
7 Dr. Roland Sackers
Chief Financial Officer, MD & Member of Management Board
70
8 Dr. Thomas Schweins
Senior Vice President of Life Science Business Area
70
9 Mr. Thierry Bernard
Chief Executive Officer, MD & Member of Management Board
70
10 Mr. Antonio Santos
Senior Vice President & Head of Global Operations
70

Qiagen N.V. Competitors

MorphoSys AG Logo
MorphoSys AG

MOR.DE

(0.8)
Symrise AG Logo
Symrise AG

SY1.DE

(2.5)
United Internet AG Logo
United Internet AG

UTDI.DE

(3.5)
Brenntag SE Logo
Brenntag SE

BNR.DE

(3.0)
Evotec SE Logo
Evotec SE

EVT.DE

(0.8)